## CENTER FOR DRUG EVALUATION AND RESEARCH

# APPLICATION NUMBER: 22-030

## **CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)**

Find authenticated court documents without watermarks at docketalarm.com.

DOCKET

RM

Δ

HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION		Office of Clinical Pharmacology Tracking/Action Sheet for Formal/Informal Consul				
From: Hyunjin Kim, Pharm.D., M.S.			To: DOCUMENT ROOM (LOG-IN and LOG-OUT) Please log-in this consult and review action for the speci IND/NDA submission			
DATE: 05/28/2008	IND No.: Serial No.:	NDA No.: 22-030 Serial No.:	DATE OF DOCUI 5/1/2008 and 6			
NAME OF DRUG PRIORITY Fesoterodine fumarate		CONSIDERATION Date of informa Consult:		ormal		
NAME OF THE SPONS	SOR: Pfizer (distributo	r), Schwarz Pharma (m	anufacturer)		· · · · · · · · · · · · · · · · · · ·	
	<u> </u>	TYPE OF SU	JBMISSION			
	CLINICAL PHAN	RMACOLOGY/BIOP	HARMACEUTICS	S RELATED I	SSUE	
IN-VITRO METABOLISM PROTOCOL PHASE II PROTOCOL DOSING REGIMEN CONSULT		] BIOAVAILABILITY STUDIES ] IN-VIVO WAIVER REQUEST ] SUPAC RELATED ] CMC RELATED ] PROGRESS REPORT ] SCIENTIFIC INVESTIGATIONS ] MEETING PACKAGE (Pre-IND)		<ul> <li>□ LABELING REVISION</li> <li>□ CORRESPONDENCE</li> <li>□ DRUG ADVERTISING</li> <li>□ ADVERSE REACTION REPORT</li> <li>□ ANNUAL REPORTS</li> <li>□ FAX SUBMISSION</li> <li>⊠ OTHER (SPECIFY BELOW):</li> <li>[complete response to AE letter]</li> </ul>		
<b> </b>		REVIEW	ACTION		······	
E-mail comments to:       Na         Medical       Chemist       Pharm-Tox         Micro       Pharmacometrics       Others		Oral communication         ame:       ]         Comments communication         ceting/Telecon. see means         ated:       ]	icated in		eview/Memo (attached) nents below hission cover letter SPECIFY BELOW):	
		<b>REVIEW CO</b>	•••			
					CATED TO THE SPONS( E)" action taken on N	
-	ted NDA 22-030 for ent of overactive bla				ease tablets on March vable action pending	
located in Sh 2. Labeling rev 2007 for the	hannon, Ireland, wh vision. Reference is	ich was not availab made to the revised discussions. If add	le during the revi l labeling by FDA itional informatio	iew cycle. A conveyed to on relating to	ity, Schwarz Pharma o the sponsor on Janu o the safety or effectiv	
01 1050101001						

- Module 2: common technical document summaries
- Module 3: quality, summary of the CMC information proposed to be included in the quality module of the complete response
- Module 5: five phase 1 clinical study reports and three study reports of uncontrolled clinical studies; Each study title and the conclusions by the sponsor are listed below.
  - i. SP857: single-dose PK in Japanese subjects (Japan); "Randomized, double blind, placebo controlled, single site, dose escalation trial to investigate safety, tolerability and pharmacokinetics of fesoterodine after single oral administration of 4, 8, and 16mg doses in 12 young healthy male Japanese subjects"
    - Relative bioavailability of the pharmacologically active compound SPM 7605 was comparable for all dose levels in Japanese subjects. SPM 7605 and it metabolites (SPM 5509, SPM 7789, and SPM 7790) showed a similar plasma concentration-time profile with each dose level
  - SP877: single-dose proportionality (US); "Randomized, open-label, 2-fold crossover trial to investigate the dose-proportionality of fesoterodine administered as single dose administration of one 4mg tablet or one 8mg tablet in 24 healthy, male subjects" (Clinical trial report submitted in the previous NDA review cycle)
    - PK data show dose proportionality for the 2 dosage strengths (4mg and 8mg) investigated.
  - iii. A0221004: multiple-dose (once daily for five days) PK in Japanese subjects (US); "A double blind, placebo controlled, multiple dose, randomized study to evaluate the safety and pharmacokinetics of fesoterodine sustained release tablets (SR) in Japanese healthy male subjects"
    - $\circ$  C<sub>max</sub> and AUC<sub>r</sub> of SPM 7605, the active metabolite of fesoterodine, increased with dose after first and multiple-dose administrations and plasma concentrations reached steady state within 48 hours.
  - iv. A0221015: multiple-dose (once daily for five days) PK in Korean subjects (Korea); "A double blind, placebo controlled, multiple dose, randomized study to evaluate the safety and pharmacokinetics of fesoterodine sustained release in Korean healthy male subjects"
    - Following single and multiple dose administrations of 4mg and 8mg once daily fesoterodine SR tablets to healthy Korean subjects, the PK profiles were consistent with those seen in Caucasian and Japanese subjects.
    - The systemic exposures of SPM 7605 increased approximately in the same proportion as the fesoterodine dose between 4mg and 8mg once daily.
  - v. A0221044: single-dose proportionality and BE (US); "A phase 1, open label, randomized, single dose, 3 way crossover study to determine bioequivalence of two dose normalized E1 formulation doses as well as between formulations (E1 and F) of similar doses of fesoterodine SR tablets in healthy subjects"
    - Dose proportionality of SPM 7605 was established between the fesoterodine 4mg (E1) and fesoterodine 8mg (E1) SR tablets.
    - Bioequivalence was established between the fesoterodine 8mg (E1) and fesoterodine 8mg (F) SR tablets
  - vi. SP669: Two-phase extension trial of SP668 to investigate the safety and tolerability of sustained release fesoterodine in subjects with overactive bladder: a double-blind phase followed by an open-label extension phase
  - vii. SP738: Long-term open-label extension trial for subjects completing the phase 3 trial of fesoterodine (SP583) for the treatment of overactive bladder syndrome
  - viii. SP739: Long-term open-label extension trial for subjects completing the Phase 3 trial of fesoterodine (SP584) for the treatment of overactive bladder syndrome

#### Background

Fesoterodine is a new chemical entity in the class of antimuscarinic agents. Fesoterodine itself is a relatively weak

Find authenticated court documents without watermarks at docketalarm.com.


pharmacokinetic and toxicokinetic studies have shown a rapid deesterification of fesoterodine to its hydroxy metabolite, SPM 7605. SPM 7605 is also formed in vivo by metabolization of tolterodine, which is approved for the treatment of symptoms of OAB.

#### **Review of submissions**

Module 1, labeling revision contains a modification of METABOLISM in the Clinical Pharmacology section. CYP2D6 was previously proposed to be a major metabolic pathway to further metabolize the major active metabolite, SPM 7605 to SPM 5509. In this current submission, the sponsor is proposing to add CYP3A4 metabolic pathway, which is responsible for metabolizing SPM 7605 to SPM 7789, along with CYP2D6 as two major metabolic pathways responsible to metabolize SPM 7605. This proposal was made based on the observation of the similar increase (2 to 2.5 fold) of the exposure of SPM 7605 in CYP2D6 poor metabolizers and subjects with CYP3A4 inhibition by ketoconazole (SP564, SP567, SP683, SP684 – studies submitted at the time of original submission; March 2006). The relevant studies will be reviewed to address the label revision proposed by the sponsor in the NDA review.

Sponsor suggests that the results of the five phase 1 clinical studies confirm that the PK of fesoterodine is dose proportional and independent of the ethnicity of subjects and that the formulation E1 is bioequivalent to the final commercial formulation (F).

• There was a change of engraving from \(\comparison to "FT" to the final formulation F product. A dissolution comparison to bridge this change in engraving was found to be acceptable by the Office of New Drug Quality Assessment (ONDQA).



b(4)

bk.

Find authenticated court documents without watermarks at docketalarm.com.

Formulation			E White film coated	E(1) <sup>b</sup> White film coated	F Light blue film coa	led
Fesoterodine tumarate Xylitof Lactose monohydrate ( Hypromellose (			$\langle$	Laga,	<u> </u>	h
Fivoramelloss /	vi behenate			no , in <u>management</u> a se a a		
Total 2.5. '	, 4u yt				)	-
•						
able 4. Composition of Formulation	f Fesoterodine Fumarate	Film Coated 8 mg SR	E	T(I) b	F	
Fesoterodine fumarate.			+ WINTE BRR COATED	White film coate	d Bhie film coate	a I
Xylitol Lactose monohydrate		<b>1967</b>		/		
Hypromellose Evoromellose	vceryl behenate				\	b
			$T \rightarrow X$		1	1
Talc	an canada a san a sa		± )		)	ł
					)	
	dd				)	
q.s.					)	
q.s.	nposition for Formulatio					
q.s.		ns E, E(1) and F Formulation E (1) White film coated	Formulation Light blue : (4mg)	n F film coated	Fomulation F Blue film coated (Smg)	
q.s.	nposition for Formulatio	Formulation E (1)	Light blue		Blue film coated	
q.s. able 5. Film Coat Con Polyvinyl alcohol Titanium dioxide Talc	nposition for Formulatio	Formulation E (1)	Light blue		Blue film coated	
q.s. able 5. Film Coat Con Polyvinyl alcohol Titarium dioxide	nposition for Formulatio	Formulation E (1)	Light blue		Blue film coated	
Polyvinyl alcohol Titanium dioxide Talc Soya lecithin Indigo camine atuminum lake	nposition for Formulatio	Formulation E (1) White film coated	Light blue		Blue film coated	
Polyvinyl alcohol Titanium dioxide Talc Soya lecithin Indigo camine atuminum lake	nposition for Formulatio	Formulation E (1) White film coated	Light blue		Blue film coated	
Polyvinyl alcohol Titanium dioxide Talc Soya lecithin Indigo camine atuminum lake	nposition for Formulatio	Formulation E (1) White film coated	Light blue		Blue film coated	
Polyvinyl alcohol Titanium dioxide Talc Soya lecithin Indigo camine atuminum lake	nposition for Formulatio	Formulation E (1) White film coated	Light blue		Blue film coated	
Polyvinyl alcohol Titanium dioxide Talc Soya lecithin Indigo camine atuminum lake	nposition for Formulatio	Formulation E (1) White film coated	Light blue		Blue film coated	

Find authenticated court documents without watermarks at docketalarm.com.

DA

Α

R

Μ

## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

#### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.